Skip to main content
Top
Published in: Pediatric Cardiology 1/2006

01-02-2006

NT-proBNP as a Marker for Persistent Cardiac Disease in Children with History of Dilated Cardiomyopathy and Myocarditis

Authors: N. Nasser, Z. Perles, A.J.J.T. Rein, A. Nir

Published in: Pediatric Cardiology | Issue 1/2006

Login to get access

Abstract

Children with myocarditis and dilated cardiomyopathy may recover clinically and echocardiographically. Plasma levels of the N-terminal segment of B-type natriuretic peptide prohormone (NT-proBNP), a sensitive marker for cardiac dysfunction, may reflect residual cardiac damage in these patients. The purpose of this study was to evaluate NT-proBNP status in pediatric patients with a history of myocarditis and dilated cardiomyopathy. Cardiac evaluation was performed and the levels of NT-proBNP were measured in 23 children who had a history of myocarditis or dilated cardiomyopathy. NT-proBNP levels were also measured in 56 age-matched control children. Nine of the 23 patients had evidence of left ventricular dysfunction (DCM group), whereas 14 had none (recovery). NT-proBNP levels were higher in the DCM group (3154 ± 2858 pg/ml) than in the recovery group (122 ± 75 pg/ml, p < 0.001) and the control group (113 ± 96 pg/ml, p < 0.001). There was no difference between the recovery and the control groups (p = 0.45), and none of the recovered patients had a NT-proBNP level higher than the upper limit of normal. The area under the receiver operating characteristics curve for the diagnosis of persistent left ventricular dysfunction was 0.984. NT-proBNP levels correlated with echocardiographically derived shortening fraction and with clinical score. NT-proBNP is a good marker for persistent left ventricular dysfunction in children who have had myocarditis or cardiomyopathy. In this group of patients, NT-proBNP levels are normal in children who recover echocardiographically, suggesting no residual hemodynamic abnormalities.
Literature
2.
go back to reference Baugman KL (2002) B-type natriuretic peptide—a window to the heart. N Engl J Med 347:158–159CrossRef Baugman KL (2002) B-type natriuretic peptide—a window to the heart. N Engl J Med 347:158–159CrossRef
3.
go back to reference Bettuzzi MG, Colaneri M, Ricciotti R, et al. (2004) Plasma natriuretic peptides in neonates and children with congenital heart disease: correlation with ventricular function, heart failure symptoms and cardiac anatomy [abstract]. Cardiol Young 14(Suppl 2):34 Bettuzzi MG, Colaneri M, Ricciotti R, et al. (2004) Plasma natriuretic peptides in neonates and children with congenital heart disease: correlation with ventricular function, heart failure symptoms and cardiac anatomy [abstract]. Cardiol Young 14(Suppl 2):34
4.
go back to reference Calabrese F, Thiene G (2003) Myocarditis and inflammatory cardiomyopathy: microbiological and molecular biological aspects. Cardiovasc Res 60:11–25CrossRefPubMed Calabrese F, Thiene G (2003) Myocarditis and inflammatory cardiomyopathy: microbiological and molecular biological aspects. Cardiovasc Res 60:11–25CrossRefPubMed
5.
go back to reference Connolly D, Rutkowski M, Auslender M, Artman M (2000) The New York University Pediatric Heart Failure Index: a new method of quantifying chronic heart failure severity in children. J Pediatr 138:644–648CrossRefPubMed Connolly D, Rutkowski M, Auslender M, Artman M (2000) The New York University Pediatric Heart Failure Index: a new method of quantifying chronic heart failure severity in children. J Pediatr 138:644–648CrossRefPubMed
6.
go back to reference Drucker NA, Newburger JW (1997) Viral myocarditis: diagnosis and management. Adv Pediatr 44:144–171 Drucker NA, Newburger JW (1997) Viral myocarditis: diagnosis and management. Adv Pediatr 44:144–171
7.
go back to reference Espiner EA, Richards AM, Yandle TG, Nicholls MG (1995) Natriuretic hormones. Endocrinol Metab Clin North Am 24:481–509PubMed Espiner EA, Richards AM, Yandle TG, Nicholls MG (1995) Natriuretic hormones. Endocrinol Metab Clin North Am 24:481–509PubMed
8.
go back to reference Friedman RA, Schowengerdt KO, Towbin JA (1998) Myocarditis. In: Garson A, Bricker JT, Fischer D, Neish S (eds) The Science and Practice of Pediatric Cardiology, 2nd edn, Willams & Wilkins, Baltimore, pp 1777–1794 Friedman RA, Schowengerdt KO, Towbin JA (1998) Myocarditis. In: Garson A, Bricker JT, Fischer D, Neish S (eds) The Science and Practice of Pediatric Cardiology, 2nd edn, Willams & Wilkins, Baltimore, pp 1777–1794
9.
go back to reference Karl J, Borgya A, Gullusser A, et al (1999) Development of a novel. N-terminal-proBNP (NT-proBNP) assay with a low detection limit. Scan J Clin Lab Invest 59(Suppl 230):177–181CrossRef Karl J, Borgya A, Gullusser A, et al (1999) Development of a novel. N-terminal-proBNP (NT-proBNP) assay with a low detection limit. Scan J Clin Lab Invest 59(Suppl 230):177–181CrossRef
10.
go back to reference Lubien E, DeMaria A, Krishnaswamy P, et al (2002) Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation 105:595–601CrossRefPubMed Lubien E, DeMaria A, Krishnaswamy P, et al (2002) Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation 105:595–601CrossRefPubMed
11.
go back to reference Mair J, Hammerer-Lercher A, Puschendorf B (2001) The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure. Clin Chem Lab Med 39:571–588CrossRefPubMed Mair J, Hammerer-Lercher A, Puschendorf B (2001) The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure. Clin Chem Lab Med 39:571–588CrossRefPubMed
12.
go back to reference Maron BJ, Isner JM, McKenna WJ (1994) Task force 3 hypertrophic cardiomyopathy, myocarditis and other myopericardial diseases and mitral valve prolapse. J Am Coll Cardiol 24:854–899CrossRef Maron BJ, Isner JM, McKenna WJ (1994) Task force 3 hypertrophic cardiomyopathy, myocarditis and other myopericardial diseases and mitral valve prolapse. J Am Coll Cardiol 24:854–899CrossRef
13.
go back to reference Masson S, Vago T, Baldi G, et al. (2002) Comparative measurement of N-terminal-brain natriuretic peptide and brain natriuretic peptide in ambulatory patients with heart failure. Clin Chem Lab Med 40:761–763CrossRefPubMed Masson S, Vago T, Baldi G, et al. (2002) Comparative measurement of N-terminal-brain natriuretic peptide and brain natriuretic peptide in ambulatory patients with heart failure. Clin Chem Lab Med 40:761–763CrossRefPubMed
14.
go back to reference Matitiau A, Perez-Atayde A, Sanders SP, et al. (1994) Infantile dilated cardiomyopathy. Relation of outcome to left ventricular mechanics, hemodynamics and histology at the time of diagnosis. Circulation 90:1310–1318CrossRefPubMed Matitiau A, Perez-Atayde A, Sanders SP, et al. (1994) Infantile dilated cardiomyopathy. Relation of outcome to left ventricular mechanics, hemodynamics and histology at the time of diagnosis. Circulation 90:1310–1318CrossRefPubMed
15.
go back to reference McGeoch G, Lainchbury J, Town GI, et al (2002) Plasma brain natriuretic peptide after long-term treatment for heart failure in general practice. Eur J Heart Failure 4:479–483CrossRef McGeoch G, Lainchbury J, Town GI, et al (2002) Plasma brain natriuretic peptide after long-term treatment for heart failure in general practice. Eur J Heart Failure 4:479–483CrossRef
16.
go back to reference Mir TS, Marohn S, Laer S, et al (2002) Plasma concentrations of N-terminal pro-brain natriuretic peptide in control children from the neonatal to adolescent period and in children with congestive heart failure. Pediatrics 110:e76CrossRefPubMed Mir TS, Marohn S, Laer S, et al (2002) Plasma concentrations of N-terminal pro-brain natriuretic peptide in control children from the neonatal to adolescent period and in children with congestive heart failure. Pediatrics 110:e76CrossRefPubMed
17.
go back to reference Nir A, Bar-Oz B, Perles Z, et al. (2004) N-terminal pro-B-type natriuretic peptide: reference plasma levels from birth to adolescence. Elevated levels at birth and in heart diseases. Acta Paediatr 93:603–607CrossRefPubMed Nir A, Bar-Oz B, Perles Z, et al. (2004) N-terminal pro-B-type natriuretic peptide: reference plasma levels from birth to adolescence. Elevated levels at birth and in heart diseases. Acta Paediatr 93:603–607CrossRefPubMed
18.
go back to reference Ohuchi H, Takasugi H, Ohashi H, et al. (2003) Stratification of pediatric heart failure on the basis of neurohormonal and cardiac autonomic nervous activities in patients with congenital heart disease. Circulation 108:2368–2376CrossRefPubMed Ohuchi H, Takasugi H, Ohashi H, et al. (2003) Stratification of pediatric heart failure on the basis of neurohormonal and cardiac autonomic nervous activities in patients with congenital heart disease. Circulation 108:2368–2376CrossRefPubMed
19.
go back to reference Richards AM, Doughty R, Nicholls G, et al (2001) Australia–New Zealand heart failure group. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin. Prognostic utility and prediction of benefit from carvedilol in chronic left ventricular dysfunction. J Am Coll Cardiol 37:1781–1787CrossRefPubMed Richards AM, Doughty R, Nicholls G, et al (2001) Australia–New Zealand heart failure group. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin. Prognostic utility and prediction of benefit from carvedilol in chronic left ventricular dysfunction. J Am Coll Cardiol 37:1781–1787CrossRefPubMed
20.
go back to reference Suda K, Matsumura M, Matsumoto M (2003) Clinical implication of plasma natriuretic peptides in children with ventricular septal defect. Pediatr Int 45: 249–254CrossRefPubMed Suda K, Matsumura M, Matsumoto M (2003) Clinical implication of plasma natriuretic peptides in children with ventricular septal defect. Pediatr Int 45: 249–254CrossRefPubMed
21.
go back to reference Tisseres P, Aggoun Y, Sierra J, et al. (2004) Comparison of the New York Heart Association (NYHA), Ross, and Pediatric Heart Failure Index (PHFI) classifications in children with left ventricular dysfunction secondary to valvular disease. Biochemical and echocardiographic correlation [abstract]. Cardiol Young 14(Suppl 2):36 Tisseres P, Aggoun Y, Sierra J, et al. (2004) Comparison of the New York Heart Association (NYHA), Ross, and Pediatric Heart Failure Index (PHFI) classifications in children with left ventricular dysfunction secondary to valvular disease. Biochemical and echocardiographic correlation [abstract]. Cardiol Young 14(Suppl 2):36
Metadata
Title
NT-proBNP as a Marker for Persistent Cardiac Disease in Children with History of Dilated Cardiomyopathy and Myocarditis
Authors
N. Nasser
Z. Perles
A.J.J.T. Rein
A. Nir
Publication date
01-02-2006
Publisher
Springer New York
Published in
Pediatric Cardiology / Issue 1/2006
Print ISSN: 0172-0643
Electronic ISSN: 1432-1971
DOI
https://doi.org/10.1007/s00246-005-1027-z

Other articles of this Issue 1/2006

Pediatric Cardiology 1/2006 Go to the issue